• Nanion Technologies: イオンチャネル研究のスマートツール

    Nanion Technologies: イオンチャネル研究のスマートツール

  • SyncroPatch 384: HTS Automated Patch Clamp

    SyncroPatch 384: HTS Automated Patch Clamp

  • SURFE²R 96SE: ラベルフリーのトランスポーターHTS

    SURFE²R 96SE: ラベルフリーのトランスポーターHTS

  • Dynamic Clamp: Patchliner

    Dynamic Clamp: Patchliner

  • 脂質二分子膜実験: Orbitシリーズ

    脂質二分子膜実験: Orbitシリーズ

  • CardioExcyte 96 SOL: 心筋の光ペーシング

    CardioExcyte 96 SOL: 心筋の光ペーシング

Our Product Portfolio

SyncroPatch 384

SyncroPatch 384

Patchliner

Patchliner

Port-a-Patch

Port-a-Patch

Port-a-Patch mini

Port-a-Patch mini

CardioExcyte 96

CardioExcyte 96

FLEXcyte 96

FLEXcyte 96

SURFE²R 96SE

SURFE²R 96SE

SURFE²R N1

SURFE²R N1

Orbit 16 TC

Orbit 16 TC

Orbit Mini

Orbit Mini

Vesicle Prep Pro

Vesicle Prep Pro

Buffer Solution

Buffer Solution

2022 - Arrhythmia variant associations and reclassifications in the eMERGE-III sequencing study

icon sp96  SyncroPatch 768 PE (a predecessor model of the SyncroPatch 384 instrument) publication in Circulation (2022)

Authors:
Glazer A. M., Davogustto G., Shaffer C. M.,Vanoye C. G., Desai R. R., Farber-Eger E. H., Dikilitas O., Shang N., Pacheco J. A., Yang T., Muhammad A., Mosley J. D., Van Driest S. L., Wells Q. S., Rinke L. L., Kalash O. R., Wada Y., Bland S., Yoneda Z. T., Mitchell D. W., Kroncke B. M., Kullo I. J., Jarvik G. P., Gordon A. S., Larson E. B., Manolio T. A., Mirshahi T., Luo J. Z.,Schaid D., Namjou B., Alsaied T., Singh R., Singhal A., Liu C., Wenig C., Hripcsak G., Ralston J. D., McNally E. M., Chung W. K., Carrell D. S., Leppig K. A., Hakonarson H., Sleiman P., Sohn S., Glessner J., the eMERGE Network, Denny J., Wie W-Q., Jr. George A. L., Shoemaker M. B., Roden D. M.

Journal:

Circulation (2022) doi:10.1161/CIRCULATIONAHA.121.055562


Abstract: 

Sequencing Mendelian arrhythmia genes in individuals without an indication for arrhythmia genetic testing can identify carriers of pathogenic or likely pathogenic (P/LP) variants. However, the extent to which these variants are associated with clinically meaningful phenotypes before or after return of variant results is unclear. In addition, the majority of discovered variants are currently classified as variants of uncertain significance, limiting clinical actionability.


Download here

Back

Nanion コーポレートブログ

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.